AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Read more here.

Most AI drug development is fueled by foundation models in biology—models that are trained on vast biological data sets and ...

Pharma and biotech companies have access to an unprecedented variety of health data, from electronic health records and ...

The "AI in Biotechnology: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for AI in biotechnology was valued at $3.8 billion in 2024. The market is ...

There's been a lot of talk about using artificial intelligence in drug development over the past year. Now, it’s a lot closer ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Weave Bio, an AI-native life sciences platform company, today announced that its AutoIND solution has received the “BioTech AI Innovation of the Year” award in the ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Developer tooling provider Anaconda Inc. today announced that it has closed a Series C funding round worth more than $150 million. Insight Partners led the investment with participation from Mubadala ...

The iShares Biotechnology ETF (NYSE: IBB) has risen for six straight months, notching its longest winning streak since 2012.

What’s the best way to bring your AI agent ideas to life: a sleek, no-code platform or the raw power of a programming language? It’s a question that sparks debate among developers, entrepreneurs, and ...